SCHEMBL30890550

SCHEMBL30890550

CC1NC(=O)[C@]2(C[C@@H](C#N)N(C(=O)[C@H](CC3CC3)N(C)C(=O)C(=CC3CC3)NC(=O)C(F)(F)F)C2)Oc2ccccc21

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27244952 1.00 — —
SCHEMBL27245067 0.89 — —
SCHEMBL30890647 0.89 — —
SCHEMBL27244797 0.86 — —
SCHEMBL30890701 0.86 — —
SCHEMBL27244802 0.86 — —
SCHEMBL30890522 0.86 — —
SCHEMBL27244629 0.78 — —
SCHEMBL27244698 0.74 — —
SCHEMBL27244694 0.74 — —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4612156-A1 ANTI-VIRAL COMPOUNDS Aligos Therapeutics, Inc. (US) 2025-09-10 — — EP disclosed
WO-2024097296-A1 ANTI-VIRAL COMPOUNDS ALIGOS THERAPEUTICS, INC. (US) 2024-05-10 — — WO disclosed
Send feedback